Thomas Andrew Crockett, CEO at KalVista Pharmaceuticals, Inc. (KALV), sold 2,300 shares at $17.02 ($39K) on 2019-12-20, disclosed to the SEC on 2019-12-26.
Scheduled sale ($39k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| KALV | SELL | 2024-02-05 | $162K | — | Filing → |
| KALV | SELL | 2023-12-28 | $361K | — | Filing → |
| KALV | SELL | 2023-11-21 | $244K | — | Filing → |